Varied investments in research, development and capital projects over the next few years as part of a broader emphasis on innovation and manufacturing reshoring.

New next-generation API manufacturing facility that will focus on small molecule medicines across several therapeutic areas, including cardiometabolic health, immunology, neuroscience and oncology. Scheduled to be operational within five years, the facility will create 615 permanent high-wage jobs plus 4,000 construction jobs.

Part of a larger, previously announced $27 billion company investment.

A new facility that will enhance technical development and manufacturing through advanced automation, robotics, and digital monitoring. The project also expands the company’s focus on biologics. 

Part of a $4 billion commitment in 2025 to U.S. capital projects.

New research and manufacturing facility, supporting vertical integration of Ratio's current and future pipeline of next-generation radiopharmaceuticals.

A five-year commitment to upgrade research and development and supply chain infrastructure. Includes a $1.2 billion investment in advanced U.S. manufacturing and digital capabilities, including a new biologics flex factory in Upper Merion, Pa., to produce next-generation respiratory and cancer medicines.

The investment will also bring AI and advanced digital technologies to GSK’s five existing sites in Pennsylvania, North Carolina, Maryland, and Montana, along with expanded drug substance, device, and auto-injector capabilities.

A $195 million plant expansion to strengthen domestic API production. Part of the company’s plan to invest $10 billion in the U.S.

Construction of a plant that will produce chlorhexidine gluconate, which is primarily used as an antiseptic and surgical disinfectant.

Germany-based company to build a 60,500-square-foot manufacturing facility dedicated to producing critical injection-molded components for medical devices and pharmaceutical packaging, as well as desiccant solutions